Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds 
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration 
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
Starlink Internet Remains Active in Iran Despite Nationwide Blackout 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift 
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
CORALVILLE, Iowa, March 27, 2017 -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that Andrew Barrett, Ph.D., Senior Director, Scientific Affairs, will present at the Sachs Associates 2nd Annual Neuroscience Biopartnering and Investment Forum being held March 27, 2017, at the New York Academy of Sciences.
Details of KemPharm's presentation are as follows:
| Event: | 2nd Annual Neuroscience Biopartnering and Investment Forum | |
| Date: | Monday, March 27, 2017 | |
| Time: | 3:20 p.m. ET | |
| Location: | New York Academy of Sciences 7 World Trade Center 250 Greenwich St., 40th Floor (D Elevator Bank) New York, NY 10007 | |
About KemPharm
KemPharm is a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its Ligand Activated Therapy (LAT) platform technology. KemPharm utilizes its LAT platform technology to generate improved prodrug versions of FDA-approved drugs in the high need areas of pain, attention deficit hyperactivity disorder (ADHD) and other central nervous system disorders. KemPharm’s co-lead clinical development candidates are KP415, an extended-release prodrug of methylphenidate for the treatment of ADHD, and KP201/IR, an acetaminophen-free formulation of the company’s immediate release abuse deterrent hydrocodone product candidate, KP201. For more information on KemPharm and its pipeline of prodrug product candidates visit www.kempharm.com.
Investor Contacts: Jason Rando / Joshua Drumm, Ph.D. Tiberend Strategic Advisors, Inc. 212-375-2665 / 2664 [email protected] [email protected] Media Contact: Daniel L. Cohen Executive VP, Government and Public Relations KemPharm, Inc. 202-329-1825 [email protected]
